Name | Number of supported studies | Average coverage | |
---|---|---|---|
natural killer cell | 21 studies | 20% ± 5% | |
CD16-positive, CD56-dim natural killer cell, human | 12 studies | 25% ± 8% | |
CD16-negative, CD56-bright natural killer cell, human | 6 studies | 25% ± 7% | |
mature NK T cell | 5 studies | 20% ± 3% | |
gamma-delta T cell | 3 studies | 19% ± 3% |
Insufficient scRNA-seq data for expression of CD244 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 99% | 275.68 | 574 / 578 | 68% | 1.93 | 785 / 1155 |
liver | 93% | 117.22 | 211 / 226 | 26% | 0.67 | 105 / 406 |
bladder | 71% | 64.00 | 15 / 21 | 47% | 2.85 | 237 / 504 |
kidney | 43% | 29.33 | 38 / 89 | 71% | 2.41 | 641 / 901 |
ovary | 91% | 131.66 | 163 / 180 | 13% | 0.23 | 56 / 430 |
spleen | 100% | 1565.62 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 1.48 | 1 / 1 |
peripheral blood | 100% | 1469.05 | 926 / 929 | 0% | 0 | 0 / 0 |
intestine | 52% | 60.41 | 507 / 966 | 45% | 1.12 | 237 / 527 |
lymph node | 0% | 0 | 0 / 0 | 93% | 7.92 | 27 / 29 |
stomach | 44% | 32.59 | 159 / 359 | 43% | 1.15 | 124 / 286 |
prostate | 64% | 50.69 | 157 / 245 | 19% | 0.30 | 96 / 502 |
uterus | 33% | 19.65 | 56 / 170 | 49% | 1.55 | 224 / 459 |
breast | 43% | 25.70 | 199 / 459 | 36% | 0.79 | 398 / 1118 |
thymus | 42% | 31.16 | 277 / 653 | 35% | 1.45 | 212 / 605 |
tonsil | 0% | 0 | 0 / 0 | 76% | 2.67 | 34 / 45 |
adipose | 74% | 139.13 | 889 / 1204 | 0% | 0 | 0 / 0 |
skin | 12% | 6.24 | 224 / 1809 | 59% | 2.43 | 277 / 472 |
pancreas | 9% | 5.28 | 29 / 328 | 46% | 1.03 | 82 / 178 |
esophagus | 31% | 18.25 | 441 / 1445 | 23% | 0.56 | 43 / 183 |
blood vessel | 45% | 46.53 | 598 / 1335 | 0% | 0 | 0 / 0 |
heart | 38% | 29.51 | 324 / 861 | 0% | 0 | 0 / 0 |
brain | 16% | 8.64 | 427 / 2642 | 20% | 0.40 | 142 / 705 |
eye | 0% | 0 | 0 / 0 | 30% | 0.95 | 24 / 80 |
adrenal gland | 16% | 7.85 | 40 / 258 | 5% | 0.96 | 12 / 230 |
muscle | 1% | 0.55 | 11 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0007165 | Biological process | signal transduction |
GO_0002250 | Biological process | adaptive immune response |
GO_0032729 | Biological process | positive regulation of type II interferon production |
GO_0060732 | Biological process | positive regulation of inositol phosphate biosynthetic process |
GO_0071663 | Biological process | positive regulation of granzyme B production |
GO_0002323 | Biological process | natural killer cell activation involved in immune response |
GO_0032757 | Biological process | positive regulation of interleukin-8 production |
GO_0045087 | Biological process | innate immune response |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0042288 | Molecular function | MHC class I protein binding |
GO_0038023 | Molecular function | signaling receptor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | CD244 |
Protein name | Natural killer cell receptor 2B4 (NK cell activation-inducing ligand) (NAIL) (NK cell type I receptor protein 2B4) (NKR2B4) (h2B4) (SLAM family member 4) (SLAMF4) (Signaling lymphocytic activation molecule 4) (CD antigen CD244) |
Synonyms | 2B4 |
Description | FUNCTION: Heterophilic receptor of the signaling lymphocytic activation molecule (SLAM) family; its ligand is CD48. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. Acts as activating natural killer (NK) cell receptor . Activating function implicates association with SH2D1A and FYN . Downstreaming signaling involves predominantly VAV1, and, to a lesser degree, INPP5D/SHIP1 and CBL. Signal attenuation in the absence of SH2D1A is proposed to be dependent on INPP5D and to a lesser extent PTPN6/SHP-1 and PTPN11/SHP-2 . Stimulates NK cell cytotoxicity, production of IFN-gamma and granule exocytosis . Optimal expansion and activation of NK cells seems to be dependent on the engagement of CD244 with CD48 expressed on neighboring NK cells (By similarity). Acts as costimulator in NK activation by enhancing signals by other NK receptors such as NCR3 and NCR1 . At early stages of NK cell differentiation may function as an inhibitory receptor possibly ensuring the self-tolerance of developing NK cells . Involved in the regulation of CD8(+) T-cell proliferation; expression on activated T-cells and binding to CD48 provides costimulatory-like function for neighboring T-cells (By similarity). Inhibits inflammatory responses in dendritic cells (DCs) (By similarity). . |
Accessions | ENST00000492063.5 [Q9BZW8-3] ENST00000322302.7 [Q9BZW8-4] ENST00000368034.9 [Q9BZW8-2] ENST00000368033.7 [Q9BZW8-1] Q9BZW8 |